Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial

MYME investigators

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial'. Together they form a unique fingerprint.

Medicine & Life Sciences